MiMedx Group, Inc. (NASDAQ:MDXG) Given Average Recommendation of "Buy" by Analysts

Shares of MiMedx Group, Inc. (NASDAQ:MDXG - Get Free Report) have been assigned a consensus rating of "Buy" from the five analysts that are presently covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have covered the stock in the last year is $12.00.

Separately, StockNews.com lowered MiMedx Group from a "strong-buy" rating to a "buy" rating in a research note on Friday, November 8th.

MiMedx Group Stock Performance

MDXG stock traded up $0.14 during midday trading on Wednesday, reaching $9.62. 516,204 shares of the company's stock traded hands, compared to its average volume of 748,114. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. MiMedx Group has a 52-week low of $5.47 and a 52-week high of $10.14. The stock has a market cap of $1.41 billion, a P/E ratio of 17.49 and a beta of 1.98. The stock's 50-day moving average is $8.51 and its 200 day moving average is $7.20.

Institutional Trading of MiMedx Group

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Blue Trust Inc. purchased a new position in shares of MiMedx Group during the 3rd quarter valued at $30,000. Point72 Asset Management L.P. bought a new stake in MiMedx Group during the second quarter valued at about $40,000. Point72 DIFC Ltd lifted its position in shares of MiMedx Group by 127.6% in the third quarter. Point72 DIFC Ltd now owns 7,626 shares of the company's stock valued at $45,000 after acquiring an additional 4,275 shares in the last quarter. Entropy Technologies LP bought a new position in shares of MiMedx Group in the third quarter worth about $64,000. Finally, Quest Partners LLC purchased a new stake in shares of MiMedx Group during the second quarter worth about $81,000. 79.15% of the stock is owned by hedge funds and other institutional investors.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.